Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)

Expected Outcome:

the project results are expected to contribute to the following outcomes:

• support for the development of EU production of stable isotopes that are essential for the manufacturing of radionuclides used in novel nuclear medicine therapies;
• strengthening of the resilience and security of the EU medical radioisotope supply chain by securing access to source materials, reducing dependence on third countries and enhancing industrial-scale production (including the sourcing of stable isotopes);
• leveraging of the knowledge and expertise of nuclear scientists, physicists and engineers in order to develop and optimise the processes for